Collector
Giriş Yap
GSK snaps up US cancer treatment firm Nuvalent in $10.6bn deal | Collector
GSK snaps up US cancer treatment firm Nuvalent in $10.6bn deal

GSK snaps up US cancer treatment firm Nuvalent in $10.6bn deal

Pharma giant GSK has sealed a $10bn deal to snap up Boston-based biopharmaceutical company Nuvalent. The FTSE 100 titan said it will pay $124 per share in cash in the agreement, marking a 40 per cent premium over what Nuvalent’s stock was trading at just before this announcement. The deal is expected to officially close [...]

Go to News Site